Lifeline BioTechnologies, Inc.

Lifeline BioTechnologies, Inc.

OOTC:LLBO
0.00
USD
+0.00
(+33.33%)
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

CEO
Caren Currier
Full Time Employees
- -
Sector
Health technology
Industry
Medical specialties
Address
2313 Hollyhill Lane Denton TX United States 76205
IPO Date
Jun 21, 2001
Website
lbti.co
Business
Lifeline Biotechnologies, Inc. (LLBO) develops and commercializes innovative medical diagnostic technologies focused on point-of-care testing for infectious diseases and critical health conditions. The company offers the ABT-7500 automated workstation, which performs nucleic acid extraction, purification, and real-time PCR amplification for detecting pathogens such as SARS-CoV-2, influenza, and other respiratory viruses; the ABT-4500 semi-automated nucleic acid extraction system for high-throughput sample preparation; and related molecular diagnostic assays and reagents for clinical laboratories and healthcare providers. These products enable rapid, accurate diagnostics with minimal hands-on time, targeting hospitals, clinics, and point-of-care settings primarily in the United States. Founded in 2010 and headquartered in Virginia Beach, Virginia, Lifeline Biotechnologies operates within the biotechnology and diagnostics industry, serving the healthcare sector with a focus on molecular diagnostics. In recent developments, the company expanded its product portfolio with enhancements to its PCR-based testing platforms to address emerging infectious disease threats as of 2025, while maintaining strategic partnerships with clinical reference labs for assay validation and distribution.